Datopotamab Deruxtecan, often abbreviated as DATO, represents a significant advancement in targeted cancer treatment. This new antibody-drug conjugate pairs an monoclonal immunoglobulin specifically focused on HER2 https://www.targetmol.com/compound/datopotamab